Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label PET study of JNJ-37822681 dopamine D2 receptor occupancy in healthy men
NL-OMON30989Not yet recruiting
- Sponsor
- Johnson & Johnson
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of JNJ-37822681 in schizophrenia, sponsored by Johnson & Johnson. Primary endpoints: Striatal dopamine D2 receptor binding and occupancy and Safety and tolerability. Planned start Sep 2007; status: not yet recruiting.
02
Drugs
JNJ-37822681
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON30989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30989.